关键词：消化性溃疡；开放式；病灶；幽门螺杆菌感染
摘 要：A peptic ulcer is an open lesion that develops on the mucosal lining of the stomach and small intestine because of the caustic effect of the gastric acids and enzymes in these organs. The symptoms of peptic ulcers are pain in the abdomen, nausea, vomiting, and bloated stomach. The major symptoms include bleeding from the ulcer, which can be life-threatening. It is detected by bloody and sticky stools, often black in color. Peptic ulcers are caused mainly by a Helicobacter pylori infection followed by the overuse of OTC NSAIDs such as Naproxen, Aspirin and Ibuprofen. Peptic ulcers can be of two types based on the site of the ulcer: gastric ulcer and duodenal ulcer.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Product Profiles

04.1.1 Nexium

04.1.2 Losec

04.1.3 Vimovo

04.1.4 Pariet

04.1.5 Selbex

04.1.6 Albis

04.1.7 Lanpra/ Prevacid

04.1.8 Dexilant

04.1.9 Takelda

05. Market Research Methodology

05.1 Market Research Process

05.2 Research Methodology

06. Introduction

07. Market Landscape

07.1 Market Overview

07.2 Market Size and Forecast

07.3 Five Forces Analysis

08. Pipeline Portfolio

08.1 Key Information for the Pipeline Candidates

08.1.1 PA32540

08.1.2 TAK-438

08.1.3 Lafutidine

08.1.4 D961H

08.1.5 PMK-S005

08.1.6 YF47623

09. Market Segmentation by Class of Drugs

09.1 PPIs

09.2 H2 Receptor Antagonists

09.3 Gastric Mucosal Protective Drugs

09.4 Antacids

09.5 Antibiotics

09.6 Prostaglandin Agonists

10. Geographical Segmentation

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

18.1 Competitive Scenario

18.1.1 Key News

18.1.2 Mergers and Acquisitions

18.2 Market Share Analysis 2013

18.3 Other Prominent Vendors & Expected Future

Vendors

19. Key Vendor Analysis

19.1 AstraZeneca

19.1.1 Key Facts

19.1.2 Business Description

19.1.3 Business Segmentation

19.1.4 Business Strategy

19.1.5 Revenue by Business Segmentation

19.1.6 Revenue Comparison 2011-2013

19.1.7 Sales Revenue by Geographical Segmentation

19.1.8 Key Developments

19.1.9 SWOT Analysis

19.1.10 Strengths

19.1.11 Weaknesses

19.1.12 Opportunities

19.1.13 Threats

19.2 Daewoong Pharmaceutical

19.2.1 Key Facts

19.2.2 Business Overview

19.2.3 Business Segmentation by Revenue 2013

19.2.4 Business Segmentation by Revenue 2012 and 2013

19.2.5 Geographical Segmentation by Revenue 2013

19.2.6 Business Strategy

19.2.7 Recent Developments

19.2.8 SWOT Analysis

19.2.9 Strengths

19.2.10 Weakness

19.2.11 Opportunities

19.2.12 Threats

19.3 Eisai

19.3.1 Key Facts

19.3.2 Business Overview

19.3.3 Comparison between Revenue, Operating Income, and

Net Income

19.3.4 Sales by Geography

19.3.5 Business Strategy

19.3.6 Key Information

19.3.7 SWOT Analysis

19.3.8 Strengths

19.3.9 Weakness

19.3.10 Opportunities

19.3.11 Threats

19.4 Takeda Pharmaceuticals .

19.4.1 Key Facts

19.4.2 Business Overview

19.4.3 Business Segmentation by Revenue 2013

19.4.4 Business Segmentation by Revenue 2013

19.4.5 Geographical Segmentation by Revenue 2013

19.4.6 Business Strategy

19.4.7 Recent Developments

19.4.8 SWOT Analysis

19.4.9 Strengths

19.4.10 Weakness

19.4.11 Opportunities

19.4.12 Threat

20. Other Reports in this Series